ERBB2 and breast cancer: Preclinical data reported by Seoane et al. demonstrated the synergistic effects of dasatinib with trastuzumab as evidenced by attenuated phosphorylated levels of Src, extracellular signal-related protein kinase (ERK) and protein kinase B (Akt) in HER2+ breast cancer [12].